FMP
Arrowhead Pharmaceuticals Announced a Deal For a NASH Asset
Nov 24, 2021 1:40 AM - Davit Kirakosyan
Image credit: FMP
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) made an announcement, according to which they reached a deal with GSK for ARO-HSD, their lead asset for NASH. The company will receive a $120 million upfront payment, up to $910 million in downstream milestones and royalties up to 20%, while GSK will receive exclusive global rights in all territories, excluding China. Non-dilutive capital should extend the runway and allow the company to focus on wholly-owned programs, which analysts believe will have a higher ROI.
Other Blogs
Sep 11, 2023 12:38 PM - Rajnish Katharotiya
P/E Ratios Using Normalized Earnings
Price to Earnings is one of the key metrics use to value companies using multiples. The P/E ratio and other multiples are relative valuation metrics and they cannot be looked at in isolation. One of the problems with the P/E metric is the fact that if we are in the peak of a business cycle, earni...
Sep 11, 2023 12:46 PM - Rajnish Katharotiya
What is Business Risk and how to Measure it with Python
One of the key aspects to do well in the stock market is to know what is business risk. It is important to understand what type of business risks a company may have. Photo by Pixabay on Pexels What Is A Business Risk? Investopedia provides a very simple definition of business risk. Busin...
Sep 11, 2023 12:49 PM - Rajnish Katharotiya
What is Price To Earnings Ratio and How to Calculate it using Python
Price-to-Earnings ratio is a relative valuation tool. It is used by investors to find great companies at low prices. In this post, we will build a Python script to calculate Price Earnings Ratio for comparable companies. Photo by Skitterphoto on Pexels Price Earnings Ratio and Comparable Compa...
